Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Ken SuzawaMichael D OffinDaniel LuChristopher KurzatkowskiMorana VojnicRoger S SmithJoshua K SabariHuichun TaiMarissa MattarInna KhodosElisa de StanchinaCharles M RudinMark G KrisMaria E ArcilaWilliam W LockwoodAlexander DrilonMarc LadanyiRomel SomwarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
KRAS mutation is a recurrent mechanism of primary and secondary resistance to MET TKIs in METex14 lung cancers. Dual inhibition of MET or EGFR/ERBB2 and MEK may represent a potential therapeutic approach in this molecular cohort.